Ambarish Pandey1, Neil Keshvani1, Colby Ayers1, Adolfo Correa2, Mark H Drazner1, Alana Lewis1, Carlos J Rodriguez3, Michael E Hall2, Ervin R Fox1, Robert J Mentz4, Christopher deFilippi5, Stephen L Seliger6, Christie M Ballantyne7, Ian J Neeland1, James A de Lemos1, Jarett D Berry1. 1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas. 2. Department of Medicine, University of Mississippi Medical Center, Jackson. 3. Division of Cardiology, Department of Internal Medicine, Wake Forest University, Winston-Salem, North Carolina. 4. Division of Cardiology, Duke Clinical Research Institute, Durham, North Carolina. 5. Inova Heart and Vascular Institute, Falls Church, Virginia. 6. Division of Nephrology, University of Maryland School of Medicine, Baltimore. 7. Section of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Abstract
Importance: African Americans have a higher burden of heart failure (HF) risk factors and clinical HF than other racial/ethnic groups. However, the factors underlying the transition from at-risk to clinical HF in African Americans are not well understood. Objective: To evaluate the contributions of left ventricular hypertrophy (LVH) and subclinical myocardial injury as determined by abnormal high-sensitivity cardiac troponin-I (hs-cTnI) measurements toward HF risk among African Americans. Design, Setting, and Participants: This prospective, community-based cohort study was conducted between July 2016 and September 2018 and included African American participants from Jackson, Mississippi enrolled in the Jackson Heart Study without prevalent HF who had hs-cTnI measurements and an echocardiographic examination at baseline. Participants were stratified into categories based on the presence or absence of LVH and subclinical myocardial injury (category 1: hs-cTnI <4 ng/L in women and <6 ng/L in men; category 2: 4-10 ng/L in women and 6-12 ng/L in men; category 3: >10 ng/L in women and >12 ng/L in men). Main Outcomes and Measures: Adjusted associations between LVH, subclinical myocardial injury, and the risk of incident HF hospitalization were assessed using Cox proportional hazards models. Results: The study included 3987 participants (2552 women [64%]; 240 (6.0%) with LVH; 1003 (25.1%) with myocardial injury) with 285 incident HF events over a median follow-up of 9.8 years (interquartile range, 8.9-10.6 years). In adjusted analyses, higher LV mass and subclinical myocardial injury were independently associated with the risk of HF with a significant interaction between the 2 (Pint < 0.001). The highest risk of HF was noted among individuals with both LVH and myocardial injury (absolute incidence, 35%; adjusted hazard ratio [aHR; vs no LVH and no myocardial injury], 5.35; 95% CI, 3.66-7.83). A significant interaction by sex was also observed. Men with LVH and subclinical myocardial injury had an almost 15-fold higher risk of HF (aHR, 14.62; 95% CI, 7.61-28.10) vs those with neither LVH nor injuries. By contrast, women with this phenotype had a nearly 4-fold higher risk of HF (aHR, 3.81; 95% CI, 2.40-6.85). Conclusions and Relevance: The combination of LVH and subclinical myocardial injury identifies a malignant, preclinical HF phenotype in African Americans with a very high risk of HF, particularly among men. This finding could have implications for future screening strategies that are designed to prevent HF in the population.
Importance: African Americans have a higher burden of heart failure (HF) risk factors and clinical HF than other racial/ethnic groups. However, the factors underlying the transition from at-risk to clinical HF in African Americans are not well understood. Objective: To evaluate the contributions of left ventricular hypertrophy (LVH) and subclinical myocardial injury as determined by abnormal high-sensitivity cardiac troponin-I (hs-cTnI) measurements toward HF risk among African Americans. Design, Setting, and Participants: This prospective, community-based cohort study was conducted between July 2016 and September 2018 and included African American participants from Jackson, Mississippi enrolled in the Jackson Heart Study without prevalent HF who had hs-cTnI measurements and an echocardiographic examination at baseline. Participants were stratified into categories based on the presence or absence of LVH and subclinical myocardial injury (category 1: hs-cTnI <4 ng/L in women and <6 ng/L in men; category 2: 4-10 ng/L in women and 6-12 ng/L in men; category 3: >10 ng/L in women and >12 ng/L in men). Main Outcomes and Measures: Adjusted associations between LVH, subclinical myocardial injury, and the risk of incident HF hospitalization were assessed using Cox proportional hazards models. Results: The study included 3987 participants (2552 women [64%]; 240 (6.0%) with LVH; 1003 (25.1%) with myocardial injury) with 285 incident HF events over a median follow-up of 9.8 years (interquartile range, 8.9-10.6 years). In adjusted analyses, higher LV mass and subclinical myocardial injury were independently associated with the risk of HF with a significant interaction between the 2 (Pint < 0.001). The highest risk of HF was noted among individuals with both LVH and myocardial injury (absolute incidence, 35%; adjusted hazard ratio [aHR; vs no LVH and no myocardial injury], 5.35; 95% CI, 3.66-7.83). A significant interaction by sex was also observed. Men with LVH and subclinical myocardial injury had an almost 15-fold higher risk of HF (aHR, 14.62; 95% CI, 7.61-28.10) vs those with neither LVH nor injuries. By contrast, women with this phenotype had a nearly 4-fold higher risk of HF (aHR, 3.81; 95% CI, 2.40-6.85). Conclusions and Relevance: The combination of LVH and subclinical myocardial injury identifies a malignant, preclinical HF phenotype in African Americans with a very high risk of HF, particularly among men. This finding could have implications for future screening strategies that are designed to prevent HF in the population.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Torbjørn Omland; Marc A Pfeffer; Scott D Solomon; James A de Lemos; Helge Røsjø; Jūratė Šaltytė Benth; Aldo Maggioni; Michael J Domanski; Jean L Rouleau; Marc S Sabatine; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2013-02-13 Impact factor: 24.094
Authors: Fjola D Sigurdardottir; Magnus N Lyngbakken; Oddgeir L Holmen; Håvard Dalen; Kristian Hveem; Helge Røsjø; Torbjørn Omland Journal: Am J Cardiol Date: 2018-02-02 Impact factor: 2.778
Authors: Stephen L Seliger; James de Lemos; Ian J Neeland; Robert Christenson; John Gottdiener; Mark H Drazner; Jarett Berry; John Sorkin; Christopher deFilippi Journal: JACC Heart Fail Date: 2015-05-14 Impact factor: 12.035
Authors: Kirsten Bibbins-Domingo; Mark J Pletcher; Feng Lin; Eric Vittinghoff; Julius M Gardin; Alexander Arynchyn; Cora E Lewis; O Dale Williams; Stephen B Hulley Journal: N Engl J Med Date: 2009-03-19 Impact factor: 91.245
Authors: Barry A Borlaug; Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2009-07-28 Impact factor: 24.094
Authors: Patrick Koo; Annie Gjelsvik; Gaurav Choudhary; Wen-Chih Wu; Wei Wang; F Dennis McCool; Charles B Eaton Journal: J Am Heart Assoc Date: 2017-09-07 Impact factor: 5.501
Authors: Ambarish Pandey; Kershaw V Patel; Wanpen Vongpatanasin; Colby Ayers; Jarett D Berry; Robert J Mentz; Michael J Blaha; John W McEvoy; Paul Muntner; Muthiah Vaduganathan; Adolfo Correa; Javed Butler; Daichi Shimbo; Vijay Nambi; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Elizabeth Selvin; James A de Lemos; Parag H Joshi Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Alana A Lewis; Colby R Ayers; Elizabeth Selvin; Ian Neeland; Christie M Ballantyne; Vijay Nambi; Ambarish Pandey; Tiffany M Powell-Wiley; Mark H Drazner; Mercedes R Carnethon; Jarett D Berry; Stephen L Seliger; Christopher R DeFilippi; James A de Lemos Journal: Circulation Date: 2020-01-14 Impact factor: 29.690
Authors: Fernando U Kay; Suhny Abbara; Parag H Joshi; Sonia Garg; Amit Khera; Ronald M Peshock Journal: Circ Cardiovasc Imaging Date: 2020-02-18 Impact factor: 7.792
Authors: Florian Rader; Stanley S Franklin; James Mirocha; Wanpen Vongpatanasin; Robert W Haley; Ronald G Victor Journal: Hypertension Date: 2019-09-16 Impact factor: 10.190
Authors: Daniel H Katz; Usman A Tahir; Debby Ngo; Mark D Benson; Yan Gao; Xu Shi; Matthew Nayor; Michelle J Keyes; Martin G Larson; Michael E Hall; Adolfo Correa; Sumita Sinha; Dongxiao Shen; Matthew Herzig; Qiong Yang; Jeremy M Robbins; Zsu-Zsu Chen; Daniel E Cruz; Bennet Peterson; Ramachandran S Vasan; Thomas J Wang; James G Wilson; Robert E Gerszten Journal: Circ Genom Precis Med Date: 2021-05-21
Authors: Matthew W Segar; Kershaw V Patel; Muthiah Vaduganathan; Melissa C Caughey; Javed Butler; Gregg C Fonarow; Justin L Grodin; Darren K McGuire; Ambarish Pandey Journal: Diabetes Care Date: 2020-06-15 Impact factor: 19.112
Authors: Neela D Thangada; Kershaw V Patel; Bradley Peden; Vijay Agusala; Julia Kozlitina; Sonia Garg; Mark H Drazner; Colby Ayers; Jarett D Berry; Ambarish Pandey Journal: J Am Heart Assoc Date: 2021-02-22 Impact factor: 5.501